Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 23, 2023 - Issue 5
Submit an article Journal homepage
1,446
Views
0
CrossRef citations to date
0
Altmetric
Response to the Letter to the Editor

Letter to the editor: reflections on the future of medical cannabis research for depression

Simon Erridgea Department of Surgery and Cancer, Imperial College Medical Cannabis Research Group, Imperial College London, London, UK;b Sapphire Medical Clinics, London, UKCorrespondence[email protected]
View further author information
,
Sajed Mangooa Department of Surgery and Cancer, Imperial College Medical Cannabis Research Group, Imperial College London, London, UKView further author information
&
Mikael H Sodergrena Department of Surgery and Cancer, Imperial College Medical Cannabis Research Group, Imperial College London, London, UK;b Sapphire Medical Clinics, London, UKORCID Iconhttps://orcid.org/0000-0002-7141-3924View further author information
ORCID Icon
Pages 481-482 | Received 06 Apr 2023, Accepted 13 Apr 2023, Published online: 20 Apr 2023

References

  • Modesto-Lowe V, León-Barriera R, Jain L. Cross-national reflections on medicinal cannabis and depression. Expert Rev Neurotherapeutics. 2023.
  • Poleszak E, Wośko S, Sławińska K, et al. Cannabinoids in depressive disorders. Life Sci. 2018;213:18–24.
  • Russo EB, Burnett A, Hall B, et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037–1043.
  • Olsson F, Erridge S, Tait J, et al. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. Expert Rev Clin Pharmacol. 2023;16(3): just-accepted. DOI:10.1080/17512433.2023.2183841
  • Pillai M, Erridge S, Bapir L, et al. A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children. Expert Rev Neurotherapeutics. 2022;22(1):1–10. DOI:10.1080/14737175.2021.2001328
  • Mangoo S, Erridge S, Holvey C, et al. Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry. Expert Rev Neurotherapeutics. 2022;22(11–12): just-accepted. DOI:10.1080/14737175.2022.2161894
  • Erridge S, Kerr-Gaffney J, Holvey C, et al. Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry. Ther Adv Psychopharmacol. 2022;12:20451253221116240.
  • Banerjee R, Erridge S, Salazar O, et al. Real world evidence in medical cannabis research. Ther Innov Regul Sci. 2022;56(1):8–14. DOI:10.1007/s43441-021-00346-0
  • Tait J, Erridge S, Sodergren MH. UK Medical Cannabis Registry: a Patient Evaluation. J Pain Palliat Care Pharmacother. 2023;1–8. DOI:10.1080/15360288.2023.2174633
  • Sarris J, Sinclair J, Karamacoska D, et al. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 2020;20(1):1–14.
  • Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995–1010. DOI:10.1016/S2215-0366(19)30401-8
  • Gedin F, Blomé S, Pontén M, et al. Placebo response and media attention in randomized clinical trials assessing cannabis-based therapies for pain: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(11):e2243848. DOI:10.1001/jamanetworkopen.2022.43848
  • Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Focus. 2018;16(4):420–429. DOI:10.1176/appi.focus.16407
  • Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53. DOI:10.1001/jama.2009.1943
  • Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. DOI:10.1176/appi.ajp.163.1.28
  • Kawka M, Erridge S, Holvey C, et al. Clinical outcome data of first cohort of chronic pain patients treated with cannabis‐based sublingual oils in the United Kingdom: analysis from the UK Medical Cannabis Registry. J Clin Pharmacol. 2021;61(12):1545–1554. DOI:10.1002/jcph.1961

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.